{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:28:26Z","timestamp":1786652906297,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Cancer"],"published-print":{"date-parts":[[2014]]},"DOI":"10.4103\/0019-509x.154058","type":"journal-article","created":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T04:19:56Z","timestamp":1427429996000},"page":"82","source":"Crossref","is-referenced-by-count":6,"title":["The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion"],"prefix":"10.4103","volume":"51","author":[{"given":"N","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-509X.154058-1","first-page":"289","volume-title":"Clinical and biologic prognostic factors in malignant pleural mesothelioma","author":"Ambrogi","year":"2012","journal-title":"Thorac Cancer"},{"key":"key-10.4103\/0019-509X.154058-2","first-page":"600","volume-title":"Vascular endothelial growth factor in pleural effusions of different origin","author":"Sack","year":"2005","journal-title":"Eur Respir J"},{"key":"key-10.4103\/0019-509X.154058-3","first-page":"9","volume-title":"Management of malignant pleural effusion: Options and recommended approaches","author":"Leung","year":"2013","journal-title":"Thorac Cancer"},{"key":"key-10.4103\/0019-509X.154058-4","first-page":"740","volume-title":"Response of a nonmalignant pleural effusion to bevacizumab","author":"Pichelmayer","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0019-509X.154058-5","first-page":"392","volume-title":"Blockage of vascular endothelial growth factor (VEGF) reduces experimental pleurodesis","author":"Teixeira","year":"2011","journal-title":"Lung Cancer"},{"key":"key-10.4103\/0019-509X.154058-6","first-page":"10397","volume-title":"TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis","author":"Yang","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/0019-509X.154058-7","first-page":"380","volume-title":"Treatment options for malignant pleural effusion","author":"Musani","year":"2009","journal-title":"Curr Opin Pulm Med"},{"key":"key-10.4103\/0019-509X.154058-8","first-page":"137","volume-title":"Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma","author":"Hirayama","year":"2011","journal-title":"Respir Med"},{"key":"key-10.4103\/0019-509X.154058-9","first-page":"2636","volume-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.154058-10","first-page":"1443","volume-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.154058-11","first-page":"370","volume-title":"Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)","author":"Castagneto","year":"2008","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.154058-12","first-page":"808","volume-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"key-10.4103\/0019-509X.154058-13","first-page":"2509","volume-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.154058-14","first-page":"73","volume-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"key-10.4103\/0019-509X.154058-15","first-page":"2332","volume-title":"Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion","author":"Du","year":"2013","journal-title":"Oncol Rep"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:27:55Z","timestamp":1786649275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0019-509X.154058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014]]}},"alternative-id":["154058"],"URL":"https:\/\/doi.org\/10.4103\/0019-509x.154058","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}